Literature DB >> 28121735

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.

Thomas G Adams1, Michael H Bloch, Christopher Pittenger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28121735      PMCID： PMC5321820          DOI： 10.1097/JCP.0000000000000659

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

Review 1.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Annu Rev Med       Date:  2014-10-17       Impact factor: 13.739

Review 2.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

3.  Effects of ketamine in treatment-refractory obsessive-compulsive disorder.

Authors:  Michael H Bloch; Suzanne Wasylink; Angeli Landeros-Weisenberger; Kaitlyn E Panza; Eileen Billingslea; James F Leckman; John H Krystal; Zubin Bhagwagar; Gerard Sanacora; Christopher Pittenger
Journal:  Biol Psychiatry       Date:  2012-07-10       Impact factor: 13.382

4.  A randomized controlled trial of intranasal ketamine in major depressive disorder.

Authors:  Kyle A B Lapidus; Cara F Levitch; Andrew M Perez; Jess W Brallier; Michael K Parides; Laili Soleimani; Adriana Feder; Dan V Iosifescu; Dennis S Charney; James W Murrough
Journal:  Biol Psychiatry       Date:  2014-04-03       Impact factor: 13.382

5.  Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Authors:  Carolyn I Rodriguez; Michael Wheaton; Jordana Zwerling; Shari A Steinman; Danae Sonnenfeld; Hanga Galfalvy; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

6.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853
  6 in total
  6 in total

Review 1.  Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Authors:  Sandra J Drozdz; Akash Goel; Matthew W McGarr; Joel Katz; Paul Ritvo; Gabriella F Mattina; Venkat Bhat; Calvin Diep; Karim S Ladha
Journal:  J Pain Res       Date:  2022-06-15       Impact factor: 2.832

Review 2.  Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Reilly R Kayser
Journal:  J Clin Psychiatry       Date:  2020-09-08       Impact factor: 4.384

Review 3.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

5.  Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.

Authors:  Giovanni Martinotti; Stefania Chiappini; Mauro Pettorruso; Alessio Mosca; Andrea Miuli; Francesco Di Carlo; Giacomo D'Andrea; Roberta Collevecchio; Ilenia Di Muzio; Stefano L Sensi; Massimo Di Giannantonio
Journal:  Brain Sci       Date:  2021-06-27

6.  Toward Synergies of Ketamine and Psychotherapy.

Authors:  David S Mathai; Victoria Mora; Albert Garcia-Romeu
Journal:  Front Psychol       Date:  2022-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.